Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia

Haematologica

Volumn 95, Issue 1, 2010, Pages 102-109

  Kienle, Dirk ^a   Benner, Axel ^b   Läufle, Carolin ^a   Winkler, Dirk ^a   Schneider, Christof ^a   Bühler, Andreas ^a   Zenz, Thorsten ^a   Habermann, Annett ^a   Jäger, Ulrich ^c   Lichter, Peter ^d   Dalla Favera, Riccardo ^e   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Division of Molecular Genetics   (Germany)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Chronic lymphocytic leukemia; Markers; Quantitative RT PCR

Indexed keywords

ATM PROTEIN; CD19 ANTIBODY; LIPOPROTEIN LIPASE; PROTEIN KINASE ZAP 70; PROTEIN P53; TRANSCRIPTION FACTOR 7 LIKE 2;

ADAM29 GENE; ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLLU1 GENE; DMD GENE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC RISK; GENOMIC INSTABILITY; GLO1 GENE; HCSL1 GENE; HUMAN; IGHV GENE; KIAA0977 GENE; MAJOR CLINICAL STUDY; MALE; MGC9913 GENE; OVERALL SURVIVAL; PCDH9 GENE; PEG10 GENE; PREDICTOR VARIABLE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPT10 GENE; SURVIVAL; TCL1 GENE; VIM GENE; ZNF2 GENE;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 73949119178     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.010298     Document Type: Article

References (46)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16): 1052-7.
2. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998;25(1):42-59.
3. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-15.
4. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-6.
5. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-54.
6. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7.
7. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4): 1410-6.
8. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGHV gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100(4):1177-84.
9. Thorsélius M, Kröber A, Murray F, Thunberg U, Tobin G, Bühler A, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107(7): 2889-94.
10. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944-51.
11. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18):1764-75.
12. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004; 363(9403): 105-11.
13. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351(9):893-901.
14. Kröber A, Bloehdorn J, Hafner S, Bühler A, Seiler T, Kienle D, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol. 2006; 24(6):969-75.
15. Kienle D, Benner A, Kröber A, Winkler D, Mertens D, Bühler A, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood. 2006;107(5):2090-3.
16. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194(11):1639-47.
17. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625- 38.
18. Haslinger C, Schweifer N, Stilgenbauer S, Döhner H, Lichter P, Kraut N, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol. 2004; 22(19):3937-49.
19. Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood. 2005; 106(2): 650-7.
20. Heintel D, Kienle D, Shehata M, Kröber A, Schwarzinger I, Mitteregger D, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia. 2005; 19(7):1216-23.
21. Van't Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica. 2006;91(1):56-63.
22. Buhl AM, Jurlander J, Jørgensen FS, Ottesen AM, Cowland JB, Gjerdrum LM, et al. Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood. 2006;107(7): 2904-11.
23. Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol. 2006; 76(6):455-64.
24. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99(10):6955-60.
25. Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006; 20(2):280-5.
26. Scielzo C, Ghia P, Conti A, Bachi A, Guida G, Geuna M, et al. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest. 2005; 115(6):1644-50.
27. Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Krömer-Holzinger E, et al. Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer. 2007;121(9):1984-93.
28. Nowakowski GS, Lee YK, Bone ND, Morice WG, Barnidge DB, Jelinek DF. Analysis of chronic lymphocytic leukemia cells identifies vimentin as a novel prognostic factor for aggressive disease. Blood. 106(11):707.
29. Kienle D, Korz C, Hosch B, Benner A, Mertens D, Habermann A, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol. 2005;23(16):3780-92.
30. Winkler D, Schneider C, Kröber A, Pasqualucci L, Lichter P, Döhner H, et al. Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL). Leukemia. 2005;19(7): 1211-5.
31. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for P Value Adjustment. J. Wiley & Sons. 1993. p. 50 and 114.
32. Pollard KS, van der Laan M. Choice of a null distribution in resampling-based multiple testing. J Stat Plan Inference. 2004; 125(1-2):85-100.
33. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med. 1999;18(17-18): 2529-45.
34. Gerds T, Schumacher M. Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J. 2006;48(6):1029-40.
35. R Development Core Team. R. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2007.
36. Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R, et al. Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1. Science. 1999;285(5435):1923-6.
37. Gachard N, Salviat A, Boutet C, Arnoulet C, Durrieu F, Lenormand B, et al. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Haematologica. 2008;93(2): 215-23.
38. Le Garff-Tavernier M, Ticchioni M, Brissard M, Salmon C, Raynaud S, Davi F, et al. National standardization of ZAP-70 determination by flow cytometry: the French experience. Cytometry B Clin Cytom. 2007;72(2):103-8.
39. Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry B Clin Cytom. 2006; 70(4):309-14.
40. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, et al. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem. 2007;53(10):1757-66.
41. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112(5):1923-30.
42. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353(9146):26-9.
43. Schaffner C, Stilgenbauer S, Rappold GA, Döhner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood. 1999;94(2):748-53.
44. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002; 99(1):300-9.
45. Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, et al. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia. 2006;20(6):1080-8.
46. Benedetti D, Bomben R, Dal-Bo M, Marconi D, Zucchetto A, Degan M, et al. Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. Leukemia. 2008; 22(1):224-6.